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 Tissue engineered constructs have proven to possess comparable mechanical and 
physical characteristics to autologous tissues making them suitable replacements for 
diseased anatomy when autologous tissue transplants are unavailable.  However, 
difficulty in reseeding the constructs with cells prevents the tissue-engineered scaffolds 
from becoming an adequate, equivalent replacement for diseased tissues when compared 
to autologous transplants.  Cells adhere to the outer surfaces of scaffolds but are 
incapable of penetrating the constructs to provide complete cellularization. If cells were 
able to populate the inner layers of the tissue, then they could likely diffuse into the 
intimal and external layers of the construct to create a fully colonized scaffold. We 
propose the use of microneedles to inject cells into the inner layers of scaffolds to evenly 
repopulate entire constructs with cells.  
 With recent advancements in microfabrication, arrays of microneedles, less than a 
millimeter in height, can be fabricated simply and cost effectively.  These microneedle 
arrays can be attached to a syringe to allow injection of cells into the interior of the 
scaffold.  Unlike traditional hypodermic needles, these microneedle arrays will allow for 
accurate and customizable penetration depth as well as a customizable distance between 
adjacent needles.  With this microtechnology, anatomically accurate distances between 
neighboring cells can be achieved, an option that has never been previously available. 
 To validate the use of microneedles for bulk cell seeding, the group injected cells 
into both decellularized carotid arteries and decellularized aortic cusps using three 
iii 
 
different arrays of microneedles. We then determined the overall cellular density in the 
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
1.1 Tissue Scaffolds 
Tissue scaffolds can be produced from polymeric derivatives or decellularized 
xenogeneic tissues.  While polymeric scaffolds are inherently nonantigenic structures 
and, therefore, do not pose the risk of eliciting an immune response, they do not exhibit 
the same mechanical or structural characteristics as native tissues.  As an alternative to 
polymeric scaffolds, xenogeneic tissues can be decellularized to create collagenous 
scaffolds that are architecturally analogous to native tissues.  Decellularization eliminates 
the possibility of an immune response, while also preserving proteins and signaling 
pathways present in the extracellular matrices of autologous tissues. 
1.1.1 Blood Vessel Anatomy and Physiology 
 Blood vessels can be classified as veins, arteries or capillaries. Each vessel serves 
as a transport route for the delivery of blood and nutrients to organs and tissues and an 
export route for the removal of metabolic wastes.  Arteries carry blood away from the 
heart and withstand higher pressures than veins.  These pressures generate a consistent 
mechanical stress on the arteries.   
Arteries are composed of three distinct tissue layers, the intima, media and 
adventitia, as shown below in Figure 1.  The three layers differ in thickness and 





Figure 1: Structure of an artery. (Ross, 2010)  The tunica intima is the thin inner layer that lines the 
lumen, the tunica media is the middle layer with concentric layers of smooth muscle cells, and the 
adventitia lines the outside of the artery (a) The histological stain shows, from left to right, the collagen 
fibers surrounding the artery, the inner bands of elastin, and a layer of endothelial cells (b). 
 
The tunica intima is a single, continuous layer of endothelial cells that lines the 
lumen of the vessel.  The endothelial cells are bound together by tight junctions and gap 
junctions.  The tightly bound endothelial layer creates a non-thrombogenic surface that 
prevents clotting and allows laminar blood flow (Ross, 2010).   If this layer is damaged, a 
thrombus will form and cause a cascade of pathological events to occur. 
The tunica media is composed mainly of smooth muscle cells that provide the 
contractile force of the artery. The smooth muscle cells secrete the collagen, elastin, and 
other proteins that make up the extracellular matrix of the media (Ross, 2010).  As blood 
flows through the artery, the smooth muscle cells constrict or relax allowing the artery to 
dilate or constrict.  Vasodilation and vasoconstriction control blood volume as well as 
allow blood pressure to be controlled and regulated.  The blood vessel must withstand 
constant, physiological pressures ranging from 80mmHg to 120mmHg (Ross 2010). 
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The outermost layer, the adventitia, is primarily composed of connective tissue 
and fibroblasts.  The adventitia prevents the artery from stretching past its physiological 
limits during vasodilation (Ross, 2010).  The adventitia contains a network of blood 
vessels called the vaso vasorum that provide nutrients and remove waste from the inner 
layers of large, conducting arteries. 
There are three different types of arteries: muscular, elastic, and arterioles; each 
differing in function and composition.  As you move further away from the heart, the 
arteries decrease in size.  The carotid artery is an elastic artery, with a thick tunica intima, 
thick media, and a thin adventitia.  The carotid artery is one of the most commonly 
diseased areas of vasculature. 
1.1.2 Blood Vessel Pathology 
Cardiovascular disease, including coronary artery and peripheral vascular disease, 
is the leading cause of mortality in western countries and often requires vascular 
reconstructive surgery (Mayo Clinic). The limited supply of suitable small-diameter 
vascular grafts has led to the development of tissue engineered blood vessel substitutes.  
Damage to blood vessels is most commonly due to a process called atherosclerosis. 
4 
 
    
Figure 2: Progression of Atherosclerosis.    Figure 3: Section of a plaque-occluded artery 
(Mayo Clinic, 2014)    (ADAM, 2014) 
 
Atherosclerosis is defined as the buildup of plaque inside of an artery (National 
Institute of Health, 2014). Plaque is a deposit of fat, cholesterol, and calcium bound 
together by a fibrous matrix.  The etiology of atherosclerosis is unknown, but studies 
have shown that its prevalence increases with smoking, poor diet, aging, and a past 
family history of heart disease.  The process begins when diseased T-cells and monocytes 
leave the blood circulation and migrate into the artery wall.  In the arterial wall, the cells 
transform into foam cells that are essentially cells that digest large amounts of cholesterol 
and fats.  In time, the smooth muscle cells in the media move into the intimal space and 
accumulate there, forming the atherosclerotic plaque (Merck Manual, 2014). 
Over time the plaque continues to grow blocking the lumen of the vessel, and 
thereby reducing blood flow.  As the size of the plaque bolus increases, it loses stability. 
Eventually the unstable plaque may rupture and form a blood clot that occludes the 
artery.  Debris of the ruptured plaque can travel through the bloodstream and become 




1.1.3 Aortic Cusp Anatomy and Physiology 
The heart beats about 2.5 billion times in a 70-year lifespan, making it the most 
mechanically stressed organ in the body. (Cleveland Clinic, 2014). The heart consists of 
four chambers; the top two atria receive blood while the bottom two ventricles pump 
blood.  The four valves of the heart function together to control the direction and flow of 
blood. Each valve is composed of either two or three leaflets that are connected to a ring 
called the annulus. The anatomy of the heart is displayed in Figure 4 below, and the 
anatomy of the aortic leaflet is shown in Figure 5. 
  
Figure 4: Heart anatomy.       Figure 5: Aortic valve anatomy. Cross section of a cusp,  
(Mayo Clinic, 2014)        showing the three layers present (Vesely, 1998). 
 
The leaflet is composed of three distinct layers: the fibrosa, spongiosa and 
ventricularis. The fibrosa is the top layer of the leaflet composed of elastin and 
circumferentially aligned collagen.  The fibrosa maintains the durability and stiffness of 
the valve, allowing it to withstand pressures up to 80mmHg (Vesely, 2004).  The middle 
layer, the spongiosa, contains glycoaminoglycans and loosely packed collagen.  This 
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layer absorbs the shock of the changing pressures by allowing the ventricularis and 
fibrosa layers to move against each other (Schoen, 2005). The ventricularis is the bottom 
layer of the leaflet composed of radially aligned elastin.  This layer responds to the 
pressure changes in the heart during the valve cycle.  
Since the aortic valve is the most stressed valve in the heart, it is correspondingly 
the valve most prone to disease and is most commonly replaced (Guyton and Hall, 2006).  
1.1.4 Aortic Cusp Pathology 
The high stress placed onto the aortic valve sometimes culminates in valvular 
damage such as microtears and calcium deposits.  Calcium is continually circulating in 
the blood stream, and microtears due to wear create crevices for the accumulation of 
calcium deposits. When calcium builds up in the valve, the leaflets become fibrotic 
producing a narrowed valve opening (Cleveland Clinic). Calcium buildup increases with 
high blood pressure and aging. 
Congenital defects can also have detrimental effects on the aortic valve.  
Congenital defects include improper valve size, malformed leaflets, or an irregularity in 
which the leaflets are attached.  In the specific case of bicuspid aortic valve disease, the 




Figure 6: Aortic valve stenosis.  The diseased aortic valve cannot open or close properly when the leaflets 
are calcified or stenotic.  This results in regurgitant flow and leakage. (Edwards Lifesciences, 2014) 
 
Although bicuspid aortic valve disease is most common, the patient can also have a 
unicuspid valve or quadricuspid valve; all of which result in a narrowing or leaky valve 
over time (Mayo Clinic). 
Infective endocarditis and rheumatic fever are two common infections that lead to 
valve failure.  Rheumatic fever, often caused by untreated strep throat infection, causes 
the leaflets to become inflamed or to stick together and become scarred, rigid or 
thickened (Cleveland Clinic).  Over time rheumatic fever can lead to the formation of 
scar tissue, creating an uneven surface on which calcium deposits can accumulate (Mayo 
Clinic).  Endocarditis is a bacterial infection in the blood stream that culminates on the 
cusps.  The bacterium causes growths on the valves and eventually leads to valve 
stenosis. 
 Aortic valve stenosis is commonly a first step in an ongoing cascade that leads to 
other serious cardiovascular pathologies.  For example, when the aortic valve narrows, 
8 
 
the left ventricle must work harder to pump blood.  To compensate for the extra work, the 
left ventricle may thicken and enlarge, leading to an overall weakening of the heart.  A 
weak heart may lead to angina, heart failure, arrhythmias and cardiac arrest (Mayo 
Clinic). 
1.1.5 Partial Conclusion 
About 600,000 people die of heart disease in the United States every year–that’s 1 
in every 4 deaths (Murphy, 2010).  The commonality of cardiovascular disease leads to a 
high demand for solutions.  In many cases of artery or valve failure, there is no easy fix 
and the entire structure must be replaced. The tissue engineering of cardiovascular tissues 
can create fully functional, integratable organ substitutes to meet this high demand. 
1.2 Microneedles 
Hypodermic needles are the standard of use for interdermal drug delivery.  
Hypodermic needles are about 25mm in length and range from 1-11mm in diameter.  
Although these needles are highly effective for the delivery drugs or small molecules to 
the patient, they have their drawbacks. Hypodermic needles cannot be safely used by the 
patient at home and often require trained assistance for use. In addition, the needles are 
painful. The length of the needle allows the tip to penetrate the dermis and disrupt nerve 
endings thereby causing pain and discomfort.  By decreasing the needle height to a 
micron level, the effectiveness of the needle as an injection device can be preserved while 
the associated pain can be eliminated.  Accordingly, a shorter needle eliminates the need 
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for trained assistance.  With recent advances in microfabrication technology, 
microneedles have now become a reality for drug delivery. 
1.2.1 Microneedle Classification 
Several different configurations of microneedles exist for subcutaneous small-
molecule delivery. These needles are classified as solid, particle-coated, dissolving, or 
hollow. Each needle type is fabricated differently to meet its intended use.   
 
Figure 7: Mechanism of delivery and classification of microneedles. (Kim, 2012). (a) The needles are 
inserted,  and pressed flush against the tissue (b) Solid: The needles are removed and drugs applied 
topically diffuse into the pores. Coated: drugs diffuse off of the surface of the needle.  Dissolving: the 
needle degrades releasing the drug suspension.  Hollow: drugs are expelled through the needle bores into 
the tissue.  
 
Solid microneedles are used for pretreatment of the skin or tissue.  The solid 
needles can be painlessly inserted into the skin and then removed to leave a micron sized 
pore in the tissue.  A drug can then be applied topically to the porated surface and 
absorbed via diffusion down into the tissue.  Solid microneedles have been sold for 
cosmetic use since 1999 when Horst Liebl founded Dermaroller, a brand selling a roller 
made of microneedles for home-use to treat scars, stretch marks, and wrinkles 
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(Doddaballapur, 2009). Solid microneedles are the easiest to fabricate out of all the 
various microneedle classes. 
Coated microneedles use a slow-release mechanism in which a water-soluble drug 
formulation diffuses off of the needle exterior into the surrounding tissue.  After an 
appropriate amount of time, the needle can be removed and the drug remains in the 
tissue.  The amount of drug released to the patient depends on the surface area of the 
needle as well as the method of coating.  Single layers of a drug can be coated onto the 
needle using a dipping or spraying method; or multiple layers can be bound to the needle 
by alternatively charging the drug positively or negatively each time a new layer is added 
(Saurer, 2010). 
Dissolving microneedles are fabricated to fully degrade upon placement in the 
tissue.  These needles are commonly constructed out of water-soluble, biodegradable 
substances that encase the drug.  Over time, the entirety of the needle will dissolve and 
the drug will diffuse locally throughout the tissue.  The use of these needles is limited to 
the formulation and properties of the drug (Kim, 2012). 
Hollow microneedles attach to a syringe and operate identically to hypodermic 
needles.  Essentially, hollow microneedles are shorter micro-versions (100um-2000um) 
of hypodermic needles.  The miniature dimensions of these needles make them much 
more complicated to fabricate then their longer, traditional counterparts. 
Preliminary studies were conducted in our lab using solid microneedles to 
determine if poration by microneedles will increase cell infiltration. Results (not 
included) showed a dramatic increase in cellular retention in dry tissues but no infiltration 
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in wet tissues.   We theorized that surface tension prevented the cells from infiltrating the 
tissue and displacing water molecules.  Based off of these results, we hypothesize that the 
use of hollow microneedles will allow the use of both hydrated and dehydrated 
scaffolds—the hollow microneedles will use the pressure of the syringe to force the cells 
into the interior layers of the scaffolds regardless of the presence of liquid molecules.  
1.2.2 Hollow Microneedle Fabrication 
Microneedles have been successfully fabricated from silicon, metal, polymer, 
glass and ceramics using a combination of photolithography, silicon etching, laser 
cutting, metal electroplating, metal electropolishing, micromolding, as well as concepts 
from microelectromechanical system engineering.  The basis for deciding which process 
to use depends on the geometry of the needle and the material. 
 The most common practice in fabricating hollow microneedles is substrate 
etching using microelectromechanical systems (MEMS), yet many other methods using 
silicon, metal and polymer molds have been successful as well (McAllister, 2003).  
MEMS evolved from the technology in semiconductor device fabrication, using micro-
scaled techniques such as wet etching, dry etching, and electro-discharge machining.  
Each of these processes involves the deposition of material layers, patterning by 
photolithography, and then etching to produce the required shapes.   An illustration of 
fabrication using MEMS was created in MEMS Pro software (softMEMS), a CAD design 





Figure 8: Process of creating hollow microneedles using MEMS (a) Silicon substrate (b) Deposition of 
SiO2 (c) Backside etching of SiO2 (d) Deep reactive ion etching (e) Deposition of Si3N4 (f) Pattern transfer 
for front side (g) Isotropic etching for needle shaft (h) Removal of SiO2 and Si3N4 (i) Final shape  (Amin, 
2013) 
 
Figure 8 above depicts the fabrication of a 200um, single, hollow, out-of-plane 
microneedle with MEMS.  First a solid block of the desired material is chosen and cut to 
the proper height.  Next, mask material is added to each side using low-pressure chemical 
vapor deposition (LPCVD).  Photoresist is then deployed over the mask material using a 
lithography process patterning.  Following this, the needle bore is formed using deep 
reactive ion etching.  LCPCVD is used again to coat and protect the needle bore.  Next, 
photoresist in deposited onto the length of the device that will not form the needle to 
protect it from future etching steps. The needle is then created using isotropic 
underetching. Finally, any remaining remnants of the oxide and nitride layers are 
removed (Amin, 2013).  
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1.2.3 Potential Applications to Tissue Engineering 
As far back as the 1970’s, scientists began experimenting with low cost 
microneedle arrays for drug delivery (Gerstel, 1976).  Only with recent advances in 
micromachining technologies has the creation of microneedles become affordable, 
effective, and reproducible.  Several studies have already been completed to validate the 
use of microneedles for the delivery of small molecules. 
Microneedle injection has proven to be an effective method for the administration 
of vaccinations, insulin, and polymeric microspheres (van der Maaden, 2014; Gupta, 
2008; Wang, 2006).  A study comparing the injection of the polio vaccine into rats using 
a hypodermic needle versus a single microneedle showed comparable IgG responses and 
antibody induction. This demonstrates that the microneedle was as equally effective as 
the hypodermic needle at delivering the vaccine to the rat (van der Maaden, 2014). The 
polio vaccine is usually delivered using a 23-25-gauge needle (OD 0.51mm-0.64mm), 
which is large enough to easily accommodate a 0.02mm cell (Immunization Action 
Coalition, 2014).  The successful delivery of a vaccine serves as a predicate for the 
successful delivery of cells. 
The flow rate of the injected solution through the microneedle has also been 
investigated. Studies conducted on human cadavers measured flow rates of 130uL/hour 
through individual needles.  This rate could be further increased with a slight retraction of 
the needle after insertion to create a pocket for the fluid to fill (Martanto, 2006).  This is 




Potential damage to the skin after repeated injection has also been a common 
cause for concern with microneedle arrays.  Post-insertion and retraction, microholes 
with diameters ranging from 100-300um in diameter remain in the skin.  These holes 
disappear within 10-20 minutes in in-vivo models and after 30 minutes there is no 
evidence of the injection (Wang, 2006).  This demonstrates that damage to the living 
tissue is minute and temporary. However, the mechanical damage to non-living tissues 
has not yet been characterized. 
Loss of cell viability with microneedle injection must also be considered. Initial 
experiments testing the shear stress experienced by cells (human fibroblasts) during 
infusion by microneedles at rates up to 100uL/second showed no loss of viability (Wang, 
2006).   The study advanced to test the injectibility of 2.8um polymeric microspheres and 
human intestinal epithelial cells.  Results showed a direct correlation between injection 
pressure and penetration depth; with higher injection pressures, both the cells and 
microspheres were able to fill the needle track and then exit the needle tip and penetrate 
the skin (Wang, 2006). 
1.3 Bulk Cell Seeding Techniques 
The aim of tissue engineering is to create structural and functional equivalents for 
the replacement of diseased anatomy.  In order to create a scaffold equivalent to native 
tissue, the scaffold must be fully repopulated with cells prior to implantation.  Bulk 




1.3.1 Bulk vs. Surface Seeding 
Cells readily adhere to the exterior surfaces of tissues, but hydrostatic forces 
prevent passive diffusion of cells into the interior of scaffolds. In order for a cell to move 
into a scaffold there must be a pathway leading to the interior, sufficient room for the cell 
to move into, and an affinity or a driving force that allows the cell to migrate to that 
space. 
  
Figure 9A: Use of microneedles to   Figure 9B: Static seeding using a pipette 
obtain bulk seeding       
 
           
Figures 9A and 9B above compare methods of bulk and static seeding.  To conduct bulk 
seeding using a microneedle, the needle must first pierce the porous scaffold to create a 
pathway down into the interior of the matrix.  The cell suspension can then be injected 
down into the channel, displacing the water in the hydrated scaffold, and allowing space 
for the cells to reside.  Next, the needle is removed and the cells bind to the peripheral 
matrix in the channel.  Contrarily, in the surface seeding process, the cells are directly 
pipetted onto the surface of the scaffold.  In this method, there is no creation of a pathway 
or a driving force that promotes cell growth into the interior of the construct.  Bulk 
seeding is much more difficult to accomplish than surface seeding, but is required in 
order to increase the functionality of the scaffold in vivo. 
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1.3.2 Requirements of seeding method 
In order for a method of cell seeding to be successful, several parameters must be 
met.  The method must not alter the device in any way that would compromise the 
biocompatibility of the vascular replacement.  No chemicals, nanoparticles, or 
electrostatic charges should alter the function or integration of the graft. 
 
 
Figure 10: Criteria for cell seeding 
 
All criteria in Figure 10 must be met in order for the method of cell seeding to be entirely 
successful. 
1.3.3 Current Methods 
Numerous methods aimed to drive cells into the middle layers of tissue scaffolds 


















accepted as the gold standard for the cellularization of scaffolds.  None of the eight 
seeding methods listed below have had total, successful results for the bulk seeding of 
arteries or cusps.  If the method does yield a high cellular density, then there exists other 
negative factors, such as seeding time or complexity, that make it an unsuitable option for 
seeding.  An alternative to these eight methods must be investigated.   
1.3.3.1 Static seeding 
Static seeding has remained the traditional method of seeding for many years due to 
its simplicity.  Static seeding is accomplished by directly pipetting a cellular suspension 
onto the surface or into the lumen of a graft, and then placing the graft in solution with 
the cell suspension to allow the cells to passively diffuse onto the tissue. In most cases 
static seeding results in surface seeding, but no diffusion of cells into the interior of 
scaffolds.  In order to get cells into the interior of tissues, several different approaches 
have been tested. 
1.3.3.2 Rotational seeding 
In rotational seeding, a graft is rotated in cell/media suspension.  Most rotational 
seeding is conducted with a spinner flask.  Spinner flasks are used to quickly and 
efficiently expand cell lines. Spinner flasks create a turbulent flow within the flask using 
an impeller blade and magnetic bar. In rotational seeding, the scaffold is placed in the 




Figure 11: Spinner Flask. The spinner flask is the most basic concept of the bioreactor.  It creates a 
constant flow throughout the culture medium, but this flow is turbulent and causes high shear stresses. 
(Martin, 2004) 
 
Rotational seeding provides a higher seeding efficiency compared to static seeding (Kim, 
1998).  The rotational method of seeding also yields an average of 27% more collagen 
production when compared to static seeding (Kim, 1998). 
Although cell density increases with rotational seeding, the cells remain on the 
periphery of the scaffolds and demonstrate no significant migration into the intimal 
layers.  Rotational seeding is not an optimal method of cell seeding because a high initial 
concentration of cells is necessary in order for any significant cell adhesion to occur to 
the scaffold. (Godbey, 2003) 
1.3.3.3 Centrifugal seeding 
Centrifugal seeding utilizes the same concepts as rotational/dynamic seeding, but 
incorporates higher centrifugal speeds, reaching up to 6000rpm (Godbey, 2004). The 
device used for centrifugal seeding is essentially a rotor from a centrifuge secured tightly 
into a large flask with raised pins that allow rotation in the XY plane.  The pins attach to 
spin tubes, in which the scaffold and cell suspension are deposited. 
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In an experiment by Godbey et al., 200,000 cells were initially seeded on three 
identical, polymeric scaffolds and then subjected to static, rotational or centrifugal 
seeding.  After 24 hours, 30,000, 35,000, and 66,000 cells were present on the scaffolds 
for static, rotational and centrifugal seeding (2500rpm) respectively (Godbey, 2004). 
Centrifugal seeding had almost two times the cellular retention as rotational seeding.   
Centrifugal seeding also facilitated a more homogenous distribution of cells 
throughout the thickness of the scaffold; however, this homogeneity was highly 
dependent on the size of cells and the corresponding pore size of the scaffold. If the cell 
size and pore size were not compatible, then the cellular retention decreased drastically 
(Godbey 2004).  Also, when rotation speeds were increased to promote faster, more 
forceful cell infiltration, cell lysis occurred.  
These constraints prevent centrifugal seeding to be used as a general method of bulk 
seeding. Centrifugal seeding is only effective when centrifugal speed, scaffold size, cell 
type, and centrifugation time are optimized for each, individual experiment. 
1.3.3.4 Vacuum seeding 
Apart from rotational seeding, vacuum seeding is the other commonly used method of 
dynamic seeding. Vacuum seeding uses a pressure differential created by a pump to force 




Figure 12: Schematic of vacuum seeding.  The cell suspension is pipetted onto the scaffolds and a 
vacuum pressure is used to pull the suspension through the scaffolds.  The vacuum force can be created by 
a syringe or by a pump. (Li, 2001) 
 
Vacuum seeding has proven to be a quick and efficient method of cell seeding (van 
Wachem, 1990).  The vacuum force traps the cells in the scaffold and increases cellular 
retention. 
Vacuum seeding, when used concurrently with a perfusion system, promotes higher 
cellular retention and generates an even distribution of cells throughout the length and 
thickness of the scaffold (Soletti, L).  Disadvantages to this method are the complexity of 
the vacuum/perfusion bioreactor, size limitations of the graft, and the necessity for 
different seeding procedures with different graft/cell combinations. 
1.3.3.5 Electrospun seeding 
Electrospinning allows the creation of a scaffold that resembles the composition of 
the ECM at the sub-micron and nanometer scale. The scaffolds can be designed to 
influence cell growth and morphology.  Studies have shown that cells cultured on aligned 
scaffolds deposit more ECM than those cultured on disorganized scaffolds (Lee, 2005). 
This suggests that a scaffold that mimics the ECM will promote greater ECM deposition. 
21 
 
In this method, cells are electrosprayed concurrently with the scaffold polymer to 
create an electrospun scaffold that has cells inherently located within the scaffold pores.  
This is accomplished through a set-up using a pump, magnetic fields and voltage fields 
(Figure 13).  The pump simultaneously releases equal amounts of cell solution and 
polymer solution onto a charged, rotating mandrel, onto which the cells and polymer then 
form a three-dimensional mesh (Stankus, 2006).  
 
Figure 13: Cellular microintegration. (A) Side by side capillary configuration to electrospray cells onto a 
flat target moving in an x-y plane. (B) Perpendicular capillary configuration to electrospray cells onto a 





Electrospun seeding is both difficult and time consuming.  After 45 minutes of 
electrospraying, the scaffold only achieves a thickness of 100um (Stankus, 2010).  
The electrospun scaffold cannot survive for extended periods without significant loss 
of cell viability.  Initially after electrospraying, the cells are evenly distributed and 
healthy, but after 4 days in static or perfusion culture, the cells began to lose viability 
because the nutrients cannot reach the interior of the matrix (Stankus, 2006).  There is 
also evidence to support that when one cell becomes necrotic, the neighboring cells 
follow similar apoptotic or necrotic pathways leading to mass cell death in the interior of 
the scaffold. Also, the effect of the high voltage on cell viability has not been analyzed. 
The mechanical properties of the scaffold also suffer with the co-integration of cells 
into the matrix.   The cells disrupt the polymer network and replace the elastic polymer 
volume with cellular volume, causing a drop in tensile strength and in breaking strain 
(Stankus, 2006). 
1.3.3.6 Magnetic seeding 
The magnetic seeding method uses ferrous particles to magnetize the cells.  The 
magnetized cells are then drawn into the scaffold by a magnetic force created by the 
placement of a magnet adjacent to the scaffold.  This method of seeding can be 
accomplished two different ways.  The cells can be magnetized by inserting magnetic 
nanoparticles into the cells, or magnetic particles can be bound to the surface of the cells.  
To bind magnetic particles to the exterior of cells, Dynabeads (DynaNiotec, Oslo, 
Norway) have been used.  Dynabeads are superparamagnetic polymer particles that bind 
to specific cells or proteins.   A magnet is inserted into the interior of the vascular graft, 
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and pulls the beads into the pores of the graft to accomplish seeding efficiencies up to 
99% (Perea, 2006). The process of cell seeding can be completed in less than one hour. 
To create a magnetic charge within the cell, a different approach is taken.  Cells are 
labeled magnetically using magnetite cationic liposomes (MCLs) and then pulled into the 
pores of the scaffold using a direct magnetic force.   
 
Figure 14: Schematic of magnetic seeding. Cells were labeled with MCL’s then added to culture medium.  
A magnet was inserted into the center of the scaffold, and then the scaffold was rolled in solution to seed 
cells evenly. (Shimizu, 2007) 
 
The MCLs are made of a magnetite lipid mixture that results in particle sizes of 150nm.  
When cells are placed in solution with MCLs, the cells readily absorb the MCLs. 
Similarly to the Dynabead study; a 99% seeding efficiency is achieved  (Shimizu, 2007).  
 Although promising, magnetic seeding has lost popularity due to the toxic side 
effects found when excessive amounts of nanoparticles are absorbed by the cell (Ito, 
2004). There have not been clear results describing how the magnetite nanoparticles 




Toxicity, in addition to a lack of in vivo studies and extended culture periods of 
magnetically seeded scaffolds in an in vitro, long-term study, has prevented the use of 
magnetic cell seeding (Shimizu, 2007).  
1.3.3.7 Perfusion/Bioreactor seeding 
Studies have shown that mechanical stresses have a beneficial effect on the properties 
of tissue engineered vascular constructs (Rouwkema, 2010).  Bioreactors create a 
physiological environment that allows for the conditioning of scaffolds to provide a better 
environment for the survival and growth of the cells in the scaffold (Barron, 2003).    
 
Figure 15: Bioreactor configuration for cell seeding. Arrows indicate the flow of culture medium 
through the scaffolds (Kitagawa, 2005) 
 
Bioreactors increase cellular retention by maximizing fluid and mass transfer into the 
scaffold under physiological pressures.  At an experimentally determined optimal 
perfusion rate, retention of seeded cells over a 5-day period increases by about 7 fold in a 
bioreactor setting (Kitagawa, 2005).    
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Although effective when optimized, seeding outcomes deteriorate when the 
concentration of cell suspension and flow rate are not experimentally determined for each 
combination of scaffold and cell type.  The need to optimize the process in an already 
complex bioreactor system causes this method of cell seeding to be extremely difficult.  
This method is also time consuming, as it requires about a week for cells to adhere and 
migrate into all layers of the tissue under continual flow conditions. 
1.3.3.8 Scaffold Coating 
In order to get cells to readily bind to scaffolds, efforts have been made to coat 
scaffolds with different biological glues such as fibrin and fibronectin, or with ECM 
proteins such as collagen or laminin (Salacinski, 2001; Pawlowski, 2003).  The goal of 
scaffold coating is to bind the cells to the matrix or to trap the cells in the matrix.  
Scaffold coating limits seeding to the periphery of the grafts and does not encourage cell 
migration into the graft.  Other concerns with scaffold coating are that cells will form 
conglomerates where the proteins are bound, and not coat the free surfaces of the graft.  
This may provide a site for thrombosis and clot formation. 
1.3.4 Partial Conclusion 
Although the various methods aforementioned demonstrate an increase in cell 
density in the interior of scaffolds, each method is flawed, often requiring long incubation 





Figure 16: Summary of existing seeding methods including advantages and disadvantages 
Method Description Advantages Disadvantages 
Static Seeding Cells pipetted onto scaffold Cheap, simple Surface seeding 
Rotational Seeding Spinner flasks mix the scaffold 
and cells together 
Increased cell-
scaffold contact 
Slow, surface seeding 
Centrifugal Seeding A device equipped with a 
centrifuge spins cells from a 
center tube out to the 




Shear damage to cells, 
only for small 
scaffolds 
Vacuum Seeding A vacuum force is used to pull 
cells down through the pores of 
the scaffold 
Simple Only works for 
simple, flat anatomy 
Electroseeding While electrospinning the 
polymer scaffold, an adjacent 
reservoir sprays a cell solution 
into the scaffold 
Cells innately 
embedded in scaffold 
Lack of research 





microparticles into cells and 









Mimics physiological conditions 
to maximize cell morphology 
and ECM remodeling 
Conditions cells Complex, long time, 
Need for optimization 
Scaffold Coating Increases cells affinity to bind to 
scaffolds through binding of 
native proteins to the scaffold 
Increased binding to 
cell surface 
Limited penetration 
Aggregates of cells 
 
We believe that an injection method of cell seeding will allow us to physically repopulate 
the scaffold to a natural cell density while also limiting the adverse effects associated 
with existing cell seeding methods. 
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CHAPTER 2: PROJECT APPROACH 
2.1 Rationale 
In order for a tissue-engineered substitute to be successful, it must not only mimic 
the native tissue but must also fully integrate into a living system. When a scaffold is 
implanted without cells present both externally and internally, thrombosis and clotting 
occur along the graft.  No seeding method exists to date that can fully cellularize a tissue 
in a short amount of time without causing mechanical or cellular damage to the construct. 
Our group believes that an injection method of seeding is the best approach for the 
reseeding of decellularized tissues. 
The goal of this master’s project has been to design and test different 
configurations of microneedle arrays to determine if these arrays are a suitable option for 
the reseeding of scaffolds.  This is the first study to determine if microneedles have the 
potential to seed scaffolds via microinjection. 
2.2 Specific Aims 
This project has three major goals: 1) Design or purchase several variations of 
microneedle arrays that vary in needle count, height, and diameter and 2) Test the ability 
of the microneedles to confluently seed the entire thickness of a scaffold 3) Determine the 
effect that repeated insertion of microneedles has on the mechanical integrity of the graft. 
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2.2.1 Aim I: Design/purchase microneedle arrays 
The microneedle array had three top design requirements: That (1) the needle 
bores be large enough to allow the passage of cell suspension without damaging the cells 
(2) the needle array sharply pierce the tissue repeatedly without damaging the needles, 
and (3) the needle lengths not exceed the thickness of the tissue. All materials were to be 
non-toxic and sterilizable. 
2.2.2 Aim II: Experimentally validate the injection method 
The ability of the microneedles to deposit cells into the medial layers of the 
scaffold was tested on two different cardiovascular tissues: aortic cusps and carotid 
arteries.  
Three decellularized aortic cusps and three decellularized carotid arteries were 
seeded using each of the three different microneedle arrays. A fourth decellularized cusp 
and a fourth decellularized artery was seeded using a hypodermic needle as a control.  
The tissues were incubated in DMEM for 8 hours to allow cells to adhere and to promote 
surface seeding.  
 Cellular assays including DAPI, Massons Trichrome, and H&E staining were 
used to evaluate cell density and migration. 
2.2.3 Aim III: Quantify mechanical damage 
Repeated insertion of the needles into the tissue may cause significant damage to the 
mechanical integrity of the scaffold.  To determine if the damage was significant, a 
uniaxial tensile test was conducted to compare mechanical differences within fresh 
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tissues, decellularized tissues, and decellularized punctured tissues. The carotid arteries 
were further tested with a burst pressure test, suture retention test and compliance test to 






CHAPTER 3: MATERIALS AND METHODS 
3.1 Microneedle Design 
A set of design criteria was composed to determine the necessary characteristics 
and design specifications of the microneedle array. 
 
 
Figure 17: Design criteria for microneedle arrays 
 
Three different microneedle arrays were tested in this study: MicronJet (Nanopass, 
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Figures 18 A, B, C: Gross images of the selected microneedle arrays (a) Micropoint array: 3x3, 1mm 
height, 300µmx300µm base hollow microneedle hub; made of stainless steel (b) AdminPen: one hundred 
eighty seven 500 µm-tall microneedles on 1cm2 circular array; made of SS316 stainless steel (c) MicronJet: 
three 600µm-tall microneedles; made of silicon 
 
Before these devices were obtained, we attempted to 3D print a microneedle array. A 
syringe-attachable microneedle array was designed in Solidworks and sent to the 
Clemson University machine shop for fabrication.   
  
Figure 19A: Solidworks designed array          Figure 19B: 3D printed array under  
                     dissection microscope 
 
The Objet350 Connex with a resolution of 16um was used to print the device out of 
VeroWhite.  Many different printing configurations and different materials were 
attempted, but the needles were unable to be printed with hollow bores or sufficiently 
sharp tips. 
A B C 
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3.2 Experimental Methods 
The following protocols were used in the experimentation, testing, and analysis of 
microneedle injection of cells into arteries and leaflets. 
3.2.1 Carotid Artery Scaffold Preparation 
Fresh carotid arteries 5–10 cm long, tapering from 6 to 3mm (Animal Technologies, 
Tyler, TX) from young porcine (6-8 weeks) were decellularized using a novel 













Figure 20: Double reservoir bioprocessing system with 12 mounted porcine carotid arteries.  The 







3.2.1.1 Cleaning and Preparation 
Once received, the carotid arteries were cleaned over ice to remove excess fat.  Luer 
lock fasteners were zip tied to each end of the arteries for future mounting into the 
bioprocessing system. To test for leaks, one luer lock was closed off with a luer cap while 
the other end of the artery was tightened onto a syringe filled with saline.  The arteries 
were pressurized and monitored for any leaks.  If a leak was observed, the hole was 
sutured with standard suturing procedures using a 3-0 Ethibond Excel braided polyester 
suture.  
Before initiating the decellularization processes, samples were treated in 30 mM 
EDTA , 0.02% Sodium Azide (NaN3)  and pH to ~7, then placed on an orbital shaker at 
3.5 rpm at 4°C to remove gross bioburden and kill bacteria. 
3.2.1.2 Tissue Decellularization and Sterilization 
The fresh arteries were subjected to a series of detergents and chemical solutions to 
remove cells and cellular debris. Ethylenediaminetetraacetic acid (EDTA) was used first 
in the decellularization process. EDTA is a chelating agent that disrupts cell adhesion to 
ECM.  EDTA works most effectively with sodium dodecyl sulfate (SDS), which is used 
to remove nuclei from tissues through a mechanism that is disruptive to ECM.   
Following SDS treatment, sodium hydroxide (NaOH) was used to eliminate 
growth factors from the matrix.  NaOH is used in short time increments because it 
disrupts collagen crosslinking. Ethanol was next used to lyse cells by dehydration. Post 
ethanol treatment, RNAse and DNAse are used to catalyze the hydrolysis of 
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ribonucleotide and deoxyribonucleotide chains. Peracetic acid was used last as 
disinfection agent that doubles as a decell agent by removing residual nucleic acids with 
minimal effect on the ECM composition and structure. 
Materials 
• 30 mM EDTA , 0.02% Sodium Azide (NaN3) (pH to 7.0) 
• 1% SDS solution in water  
• 0.1 M NaOH solution  
• 70% ethanol (EtOH)  
• ddH2O for rinsing 
• 1x PBS  
• 0.1% v/v peracetic acid solution in 1x PBS at pH 7.0 
• Sterile water  
Methods 
1. Place samples in 30 mM EDTA , 0.02% Sodium Azide (NaN3) on an orbital shaker at 3.5 rpm in 
the cold room overnight 
2. Mount the arteries in the perfusion bioreactor (Fercana) 
3. Fill the bioreactor with 30 mM EDTA , 0.02% Sodium Azide (NaN3) solution and leave overnight 








5. After the ddH2O protocol, start draining the water. 
6. Introduce the 1% SDS solution into the reservoir in 500 mL increments. 
a. Incubate for 12 days. 
b. Change 1% SDS solution after 6 days. 
7. After 12 days, conduct ddH2O Rinse Protocol 
8. Introduce ddH2O as an overnight rinse step with pressure. 
9. Conduct three – 1 L infusions of 70% ethanol (ETOH): 
a. Introduce 70% EtOH in 500 mL increments; after 1 L introduced, pressurize system and 
close waste circuit to allow 70% EtOH to circulate with pressure for 1 hour. 
b. Repeat ‘a’ 2 more times for a total of 3 hours of 70% EtOH circulation with pressure. 
10. Repeat ddH2O Rinse Protocol. Using the last 500 mL of  
11. Rinse with ddH2O for 30 min with pressure. 
ddH2O protocol 
Materials 
      •  16L ddH2O  
Methods 
1. Flush 0.5L ddH2O through each reservoir, then clamp off the 
system and add another 0.5L to allow the partial mixing before 
drainage. Drain the water 
2. Refill each reservoir with 1L of ddH2O and pressurize the system to 
allow the water to rinse the entire system. Drain the system 




12. While draining water out of system and into waste carboy, introduce the 0.1M NaOH solution into 
the reservoir in 500 mL increments. 
a. After 1400 mL of 0.1M NaOH introduced into system, incubate for 2 hours with pressure 
13. After 2 hours, conduct ddH2O Rinse Protocol  
14. Conduct one – 1400 mL infusion of 1x PBS: 
a. Introduce 1x PBS in 500 mL increments; after 1400 mL is introduced, pressurize system 
and close waste circuit to allow 1x PBS to circulate with pressure for overnight. 
15. Treat scaffolds with DNAse/RNAse solution for 96 hours at room temperature. 
a. 720 mUnits/mL DNAse, 720 mUnits/mL RNAse, 5 mM MgCl, in 1x PBS – adjust pH to 
7.5 
b. Add antibiotic/antimycotic 1% to prevent contamination during this step. 
16. After DNAse/RNAse treatment, conduct one – 1400 mL infusion of 1x PBS: 
a. Introduce 1x PBS in 500 mL increments; after 1400 mL is introduced, pressurize system 
and close waste circuit to allow 1x PBS to circulate with pressure for 1 hour. 
MOVE SYSTEM INTO A STERILE HOOD 
17. Conduct ddH1O water rinsing protocol – should not be overnight; need PBS to neutralize acid on 
same day. 
18. Conduct two – 1400 mL infusions of 1x PBS (sterile), the last 500 mL will circulate with pressure 
for 20 min. 
19. Place in peracetic acid, the last 500 mL will circulate for 2 hours with pressure, room temperature 
a. Must shake reservoir and dampener (capped) vigorously for 1 minute each, once an hour 
to ensure sterility of each bottle. 
 
3.2.1.3 Tissue Fixation 
Following decellularization and sterilization, scaffolds were stabilized with sterile-
filtered 0.15 % pentagalloyl glucose (PGG, N.V. Ajinomoto OmniChem S.A., Wetteren, 
Belgium) in 50 mM dibasic sodium phosphate buffer with 20% isopropanol in saline, at 
pH 5.5 and room temperature, without perfusion or pressure, for 24 hours. 
 
Materials 
• 0.15% w/v PGG solution in 50 mM HEPES pH 5.5 with 20% isopropanol. Sterile filter before use. 
• 70% ethanol (EtOH) (One – 1400 mL infusion per bioreactor) 
Methods 
1. Fill the whole system with sterile PGG. Treat for 24 hours at room temperature, no perfusion, and 
no added pressure. 
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2. Next day, administer two – 1400 mL infusions of 1x sterile PBS; the last 500 mL administered 
will circulate, with pressure, for 10 minutes. 
3. Administer one – 1400 mL infusion of 70% ethanol; the last 500 mL to circulate with pressure for 
10 min. 
4. Conduct ddH2O rinsing protocol with sterile water 
5. Administer one – 1400 mL infusion of 1x sterile PBS, with the last 500 mL circulating with 
pressure, for 24 hours. 
6. Repeat this step daily for a total of 6 days. 
7. In sterile hood: remove arteries, cut off barbed adaptors 
8. Store arteries in sterile 1x PBS + 1% antiobiotics/antimycotics at 4°C 
 
3.2.2 Aortic Cusp Scaffold Preparation 
The aortic cusps were decellularized with a thirteen-day immersion decellularization 
process. 
3.2.2.1 Cleaning and Preparation 
Aortic valves were removed from fresh porcine hearts, and collected from a local 
USDA approved abattoir, Snow Creek Meat Processing in Seneca, SC. Aortic roots were 
dissected up to sino-tubular junction, with 5-10 mm long coronaries, and down to 5-10 
mm beyond the base of the cusps.  Valves were collectively stored in a 500mL bottle of 
ddH2O over ice during transportation to the laboratory.   Fat and extraneous tissue were 
cut away from the aortic root.  The root was rinsed 3 times in ddH2O, and then incubated 
in ddH2O overnight at 4°C. 
3.2.2.1 Tissue Decellularization and Sterilization 
The bulk of cellular removal was accomplished with sodium hydroxide and an 
SDS/TRIS solution.  After this, the detergents were rinsed from the arteries with PBS and 
sterile water.  RNAse and DNase were then used to remove any remnants of cellular 
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debris.  These solutions were then rinsed away with PBS to prepare for tissue 
sterilization.  The sterilization was accomplished with peracetic acid. 
Materials 
• ddH2O 
• 0.05 M NaOH [Fisher BP359-500]  
• Decell solution (need 1000 mL)  
o 50 mM TRIS [EMD TX1529-5]  
o 0.25% SDS [JT Baker 4095-02]  
o 0.5% DOC [Fisher BP349-100]  
o 0.5% Triton X100 [Alfa Aesar A16046]  
o 0.2% EDTA [Sigma Aldrich E6511]  
o pH to 7.4±0.05 
o fill to 1000 mL with ddH2O 
• 0.02% Sodium azide [Fisher S227I-100]  
• 70% EtOH 
• 1xDPBS [from 10x – Mediatech 20-031-CV] (need 6-8 L) = 1x concentration, no calcium or 
magnesium 
• 0.02% Sodium azide in 1xDPBS  
• DNase/RNase  
o 0.02% NaN3  
o 5mM MgCl2 [Fisher M33-500] 
o 360 mU/mL DNase (Worthington cat#: 2139 lot#: S7D9604A, 3480u/mgDW) 
o 360 mU/mL RNase (Fisher cat#: BP2539250 lot#: 131006, 97.1 KUNITZ/mg) 
o fill to 2 L with 1xDPBS 
• Sterile 1xDPBS = 1x concentration, no calcium or magnesium 
• Sterile 0.1% Peracetic acid [Sigma Aldrich 269336] 




1. Rinse with ddH2O (3x) 
2. Incubate in 0.05M NaOH 2 hour at room temperature on a shaker 
a. Start timer for 2 hours  
3. Rinse with ddH2O (3x) 
4. Incubate in ddH2O 15 minutes at room temperature on a shaker (3x) 
5. Incubate in decellularization solution 48±3 hours at room temperature on a shaker 
6. Rinse with ddH2O (5x) 
7. Incubate in ddH2O 5 minutes at room temperature on a shaker (5x) 
8. Incubate in 0.02% Sodium azide 20±2 hours at room temperature on a shaker 
9. Rinse with ddH2O (3x) 
10. Incubate in 70% EtOH 2 hours at room temperature on a shaker 
11. Replace with fresh 70% EtOH and incubate 2 hours at room temperature on a shaker 
12. Rinse with ddH2O (2x) 
13. Incubate in ddH2O 15 minutes at room temperature on a shaker (3x) 
14. Incubate in 0.02% Sodium azide 20±2 hours at room temperature on a shaker 
15. Incubate in 1xDPBS 5 minutes at room temperature on a shaker (3x) 
16. Incubate in 0.02% Sodium azide in 1xDPBS 24±2 hours at room temperature on a shaker 
17. Incubate in 1xDPBS 5 minutes at room temperature on a shaker (3x) 
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18. Incubate in DNase/RNase solution 24±2 hours at 37°C (oven, incubator, or warm room) on a 
shaker 
a. Note: ensure that the DNase/RNase solution is pre-warmed 
19. Replace with fresh DNase/RNase solution and incubate 24±2 hours at 37°C on a shaker 
20. Rinse with 1xDPBS (2x) 
21. Incubate in 1xDPBS 15 minutes at room temperature on a shaker (3x) 
22. Incubate in 0.02% Sodium azide in 1xDPBS 24±2 hours at room temperature on a 
shaker 
23. Transfer valves into new, sterile jars 
24. Fill jars with sterile 0.1% Peracetic acid and incubate for 2 hours at room temperature on a shaker 
25. Aspirate jars until empty and rinse with sterile 1xDPBS 
26. Aspirate jars until empty and incubate in sterile 1xDPBS for 1 hour at room temperature on a 
shaker 
27. Aspirate jars until empty and incubate in sterile 1xDPBS for 2 hours at room temperature on a 
shaker 
 
3.2.2.2 Tissue Fixation 
Following decellularization and sterilization, scaffolds were stabilized with sterile-
filtered 0.15 % pentagalloyl glucose (PGG, N.V. Ajinomoto OmniChem S.A., Wetteren, 
Belgium) in 50 mM dibasic sodium phosphate buffer with 20% isopropanol in saline, at 
pH 5.5 and room temperature for 21 hours.  The scaffolds were then rinsed and stored in 
sterile PBS. 
Materials 
• Sterile cotton balls (need about 15-20 pieces for 5 valves) = autoclaved 
• 0.15% PGG solution (need 500 mL) 
o For PGG stock: 0.15% PGG (0.75 g for 500 mL) dissolved in 100 mL isopropanol;  
o For phosphate buffer: 50 mM Na2HPO4 (2.84 g for 500 mL), 0.9% NaCl (3.6 g for 500 
mL), in 350 mL ddH2O, pH to 5.5±0.05, fill to 400 mL with ddH2O;  
o To make 0.15% PGG solution: slowly add 100 mL PGG stock to the 400 mL phosphate 
buffer under constant stirring, run through 0.22 µM sterile filter into a sterile bottle 
o Protect from light by wrapping bottle in aluminum foil 
Methods 
1. Aspirate jars until empty and pack up cusps with PGG-soaked sterile cotton balls 
2. Incubate in 0.15% PGG for 21±1 hours on shaker wrapped in aluminum foil 
3. Aspirate jars until empty and remove cotton balls with sterile tools and discard 
4. Rinse with sterile 1xDPBS  
5. Aspirate jars until empty and incubate in sterile 1xDPBS for 1 hour on shaker 
6. Aspirate jars until empty and incubate in sterile 1xDPBS for 19±1 hours on shaker 
7. Aspirate jars until empty  
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8. Transfer remaining valves to sterile 50 mL conical tubes (maximum of 4 per tube) 
9. Store valves in sterile 1xDPBS at 4oC 
3.2.3 Cell Culture 
Human adipose derived stem cells (hADSCs) were subcultured in DMEM 
supplemented with 10%FBS and 1% antibiotic/antimycotic. Cells were incubated in a 
humidified atmosphere at 95% air and 5% CO2 at 37°C.  Monolayer cultured hADSCs at 
the passage numbers of 6-11 were harvested with trypsin and used for experiments. 
3.2.4 Cell Seeding 
The carotid arteries were cut down to 2cm cylinders. hADSCs were suspended at 
4x106 cells/mL in culture media and 400 µL were injected through the adventitia into the 
artery with a syringe and repeating dispenser (Hamilton Company, Reno, Nevada) using 
10 µL of cell suspension per injection, and applying an even pattern of injections across 
the artery exterior.  Each time the needles were inserted, the dispenser was pressed 2 or 3 
times to ensure the cells entered the tissue. The artery was cultured in static conditions for 
8 hours in Dulbecco’s modified Eagle’s medium, 10% fetal bovine serum, and 1% 
antibiotic solution (Corning-Cellgro). 
For the aortic cusps, hADSCs were suspended at 4x106 cells/mL in culture media 
and 500 µL were injected into each cusp with a syringe and repeating dispenser 
(Hamilton Company, Reno, Nevada) using 10 µL of cell suspension per injection, and 
applying an even pattern of injections across both sides of the cusp.  Each time the 
needles were inserted, the dispenser was pressed 2 or 3 times to ensure the cells entered 




3.2.5 Hemotoxylin and Eosin 
Hematoxylin & Eosin (H&E) staining is a customary staining method in 
histology. It uses the basic dye, hematoxylin, to color basophilic structures a blue-purple 
hue. The acidic dye, eosin, colors eosinophilic structures, such as cytoplasm and some 
extracellular matrix products, bright pink (Ross, Kaye et al., 2003). 
 Following fixation in 10% formalin, cusps and arteries were cut in half, embedded 
in paraffin wax, sectioned, and stained according to the following routine H&E staining 
method.  
 
1. Xylene  ---------------------- 10 dips 
2. Xylene  ----------------------- 5 min 
3. 100% EtOH ----------------- 10 dips 
4. 100% EtOH ----------------- 1 min 
5. 95% EtOH ------------------ 10 dips 
6. 95% EtOH ------------------ 1 min 
7. Running Water -------------Till Clear 
8. Distilled Water ------------- 1 min 
9. Hematoxylin --------------- 5 min 
10. Running Water -------------Till Clear 
11. Clarifier ---------------------10-15 dips 
12. Running Water -------------Till Clear 
13. Bluing ----------------------- 1 min 
14. Running Water ------------- 30 sec 
15. 95% EtOH ------------------ 10 dips 
16. Eosin ------------------------ 45 sec 
17. 95% EtOH ------------------ 10 dips 
18. 95% EtOH ------------------ 10 dips 
19. 100% EtOH ---------------- 10 dips 
20. 100% EtOH ---------------- 10 dips 
21. 100% EtOH ---------------- 10 dips 
22. Xylene  ---------------------- 10 dips 




DAPI (4'-6-Diamidino-2-phenylindole) is a florescent stain that will pass through 
an intact cell membrane and bind strongly to double stranded DNA. It is the standard in 
fluorescence microscopy to stain both live and fixed cells with an emission of bright blue 
fluorescence (Invitrogen, 2006). 
 After performing routine H&E staining, DAPI staining helped validate the 
presence of nucleic acids that were difficult to distinguish. Each fixed and paraffin-
embedded section was brought back to water according to the following steps and stained 
directly on the slide.  
 
1. Xylene  ---------------------- 10 dips 
2. Xylene  ---------------------- 5 min 
3. 100% EtOH  ---------------- 10 dips 
4. 100% EtOH  ---------------- 1 min 
5. 95% EtOH ------------------ 10 dips 
6. 95% EtOH ------------------ 1 min 
7. Running Water -------------Till Clear 
3.2.7 Massons Trichrome 
 Masons trichrome is a stain for collagen fibers. Collagen stains dark blue, nuclei 
stain black, and muscle and cytoplasm stain pink. After performing other routine staining, 
Massons Trichrome staining helped distinguish the damage to the collagen in the scaffold 
due to the forced insertion of the microneedles. Each fixed and paraffin-embedded 
section was rehydrated and stained according to the following routine Massons 
Trichrome staining procedure. 
 
1. Deparaffinize and rehydrate through 100% alcohol, 95% alcohol 70% alcohol. 
2. Wash in distilled water. 
3. Re-fix in Bouin's solution for 1 hour at 56 C to improve staining quality  
4. Rinse running tap water for 5-10 minutes to remove the yellow color 
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5. Stain in Weigert's iron hematoxylin working solution for 10 minutes 
6. Rinse in running warm tap water for 10 minutes 
7. Wash in distilled water 
8. Stain in Biebrich scarlet-acid fuchsin solution for 10-15 minutes. Solution can be saved for future 
use 
9. Wash in distilled water. 
10. Differentiate in phosphomolybdic-phosphotungstic acid solution for 10-15 minutes or 
until collagen is not red. 
11. Transfer sections directly (without rinse) to aniline blue solution and stain for 5-10 minutes.  
12. Rinse briefly in distilled water and differentiate in 1% acetic acid solution for 2-5 minutes. 
13. Wash in distilled water. 
14. Dehydrate very quickly through 95% ethyl alcohol, absolute ethyl alcohol (these step will wipe 
off Biebrich scarlet-acid fuchsin staining) and clear in xylene. 
15. Mount with resinous mounting medium. 
 
3.2.8 Uniaxial Tensile Testing 
Uniaxial tensile testing determines the yield stress and the elastic modulus of the 
specimen. This test is standardized in accordance with the American National Standards 
Institute/ Association for the Advancement of Medical Instrumentation (ANSI/AAMI) 
Section 7198:8.3.2.  To test the arteries, the tubular scaffold was cut down to a length of 
2cm (n = 3 per group) and both ends were clamped to the jaws of a 100N MTS test frame 
(MTS Systems Corp., Eden Prarie, MN). The sample was then stretched at a uniform rate 
of 10 mm/min until the yield and/or break point was reached. Throughout the test 
procedure the artery was continually wetted with PBS. The load at yield or break was 
recorded.   
To test the cusps, a rectangle was cut from the cusp.  The length of the cusp was 
maximized in the circumferential direction. The thickness and width of the cusp was 
measured and both ends of the rectangular section were clamped into the jaws of the 
100N MTS test frame. The sample was then stretched at a uniform rate of 10 mm/min 
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until the yield and/or break point was reached. Throughout the test procedure the cusp 
was continually wetted with PBS. 
3.2.9 Suture Retention Testing- Carotid Arteries 
Suture retention strength calculates the anastomotic strength of an arterial graft.  
This test is standardized in accordance with the American National Standards Institute/ 
Association for the Advancement of Medical Instrumentation (ANSI/AAMI) section 
7198:8.8.  Suture retention strength was calculated by cutting arterial scaffolds (n =  4 per 
group) normal to the long axis into 6x20mm segments, clamping one end to an 100N 
MTS test frame (MTS Systems Corp., Eden Prarie, MN), and placing a single 3-0 braided 
polyester suture 2mm from the free edge and looped around the test frame. Sections were 
then preloaded to 0.009N and extended to failure at 5mm/min and final data expressed as 
grams-force. The force required to pull the suture through the prosthesis or cause the wall 
of the prosthesis to fail was recorded. 
3.2.10 Burst Pressure- Carotid Arteries 
Burst pressure is important when determining the maximum amount of pressure 
an artery can withstand without breakage. This test is standardized in accordance with the 
American National Standards Institute/ Association for the Advancement of Medical 
Instrumentation (ANSI/AAMI) Section 7198:8.3.3.  
Using the calipers, the wall thickness of the vascular scaffold on both ends as well 
as the total length of the vascular scaffold was measured.  An appropriately sized luer 
fitting was placed into vascular scaffold’s lumen, one side at a time, and secured with a 3-
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0 braided polyester suture and then fastened with a zip tie. The artery was cut so that 
there was 2.0cm between the ends of the proximal and distal fitting.  A circuit with a 
peristaltic pump, pressure transducer, and distilled water fluid reservoir was built. A data 
acquisition device was attached to the pressure transducer (DAQ) to allow accurate 
reading of the transducer.  The pump was turned on and the internal pressure at which the 
artery burst was retrieved by DAQ software. For each condition n = 3 specimens were 
tested. 
3.2.11 Compliance- Carotid Arteries 
Diametrical compliance testing required a syringe pump and pressure transducer in 
addition to a digital camera. A 50mL luer lock syringe was filled with distilled water and 
connected to the artery that was connected to the pressure transducer. A metric ruler was 
secured next beneath the artery to act as a scale for later interpretation of the change in 
diameter. To determine compliance, arterial scaffold segments were exposed to 80mmHg 
then 120mmHg.  At each pressure a digital image of the artery was taken. Images were 
then imported into Image J software (National Institutes of Health, Bethesda, MD) to 
measure external diameters at three positions perpendicular to the scaffold margins for 
each image. Diametrical compliance was then calculated by inputting mean values into to 
equations proposed by Hamilton’s group and expressed as percentage distension per 




The results of the microneedle seeding study are shown below.  The histological 
results compare the seeding results of a 30-gauge needle to the Micropoint 9-microneedle 
hub.  Only the Micropoint Technology, 9-needle hub was used in the study due to the 
failure of the other two devices.  The Nanopass, MicronJet array shattered upon contact 
with the first tissue and the AdminMed, AdminPen was incapable of delivering fluid 
through the needle bores.  These failures will be addressed in further detail in the 
discussion. 
3.3.1 Carotid Artery 
3.3.1.1 Tissue Decellularization 
To verify the decellularization of the tissue, H&E was used to both detect the 
presence of nuclei and to visualize any potential damage of the ECM due to the 
decellularization process. Figure 21D shows the structure and composition of a fresh, 
porcine carotid artery prior to decellularization and Figure 21A and Figure 21D show the 
artery after decellularization. No nuclei were seen in the H&E sections and the 
organization of the extracellular matrix remained in tact.  
In addition to histology, ethidium bromide agarose gel electrophoresis was performed 
to separate fragments of DNA for quantification (Figure 21C). 
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Figure 21: Verification of decellularization process. (a,d) H&E stain of decellularized porcine carotid 
artery showing an organized ECM structure and no presence of cells. Collagen=light purple/pink and 
elastin=dark purple/pink (b) H&E stain of a fresh porcine carotid artery with a high nucleic acid content. 
Nuclei=dark purple (c) Image of electrophoresis gel. Nucleic acids emit red light.  The two left columns are 
fresh carotid arteries and the seven columns to the right of those are decellularized carotid arteries. 
 
The absence of red light in the right seven lanes of the gel indicates that decellularization 
is complete. Although there is no direct numerical quantification of the remaining DNA 
with this method, the gross visualization associated with electrophoresis is accurate 




DAPI was used to detect the presence of nuclei. A high number of blue stained nuclei 
represent a large number of cells seeded within the scaffold (Figure 22A and Figure 
22B). 
 
Figure 22: DAPI staining to compare cellular presence after injection with 30G and 9-microneedle 
hub. Nucleus=blue. (a,b) Injection with a 30 Gauge needle (c,d) Injection with 9-microneedle hub 
 
With the 30G needle, twenty 10uL boluses were pushed into the media of the artery.  In 
(a) a single cell can be seen in the bottom right and (b) shows a few cells in the middle of 
the slide but overall there is a low cellular density with the 30G needle. The 9-






Cells were not populous after seeding with the 9-microneedle hub or with the 30-
gauge needle.  In Figure 23A, there are some cells lining the lumen of the artery, and also 
located in the pocket in the tunica media.  It is uncertain whether the needle created this 
pocket.  In Figures 23B and 23C there are cells both internally and externally lining the 
surfaces of the arteries.  Surface seeding is not intended with the use of microneedles. 
Figure 23: H&E staining to compare cellular presence after injection with 30G and 9-microneedle 
hub. (a) Injection with 30G needle (b,c) Injection with 9-microneedle hub 
 
The break in the adventitia shown in Figure 23C may be indicative of where the 
microneedle penetrated the artery. Around this site, there appears to be a larger number of 
cells compared to other locations.   
49 
 
3.3.1.4 Massons Trichrome 
Surface seeding along the lumen and adventitia of the arteries is noted, but there is no 
visible cellular infiltration in either of the stains (Figure 24A and Figure 24B). However, 
the presence of cells may go undetected since they stain the same reddish color as the 
elastin. 
Figure 24: Massons Trichrome staining to detect cellular presence after injection. Collagen = blue, 
nuclei = dark red/ purple, cytoplasm = red/pink (a) Injection with 30G needle (b) Injection with 9-
microneedle hub 
 
3.3.1.5 Uniaxial Testing 
A tukey test in conjunction with an ANOVA to determine means that are significantly 
different from each other was performed for each mechanical test using SAS Studio 
(SAS, Cary, NC).   Results showed that there is no statistically significant difference in 
the ultimate tensile stress or in Young’s modulus amongst fresh tissues, decellularized 
tissues, and decellularized tissues with repeated injections of PBS. 
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Figure 25: Uniaxial tensile testing to compare fresh, decell, and decell+needle scaffolds. ^ indicates 
that the value was derived from literature in the field. (a) Ultimate tensile strength (n=2 Decell, n=2 
Decell+Needle) ^ from Campbell, 2005 (b) Young’s Modulus (n=2 Decell, n=2 Decell+Needle) ^ from 
Campbell, 2005 (c) Stress-strain curve used to determine ultimate tensile stress and young’s modulus 
 
It can be concluded that needle piercings through the cusp have no significant effect on 
the mechanical strength of the arterial scaffold. 
3.3.1.6 Suture Retention 
Figure 26 shows the suture retention strength of fresh arteries, decellularized arteries, 
and decellularized arteries with microneedle injections of 1X PBS. The suture retention 
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strength of the decellularized scaffolds exceeds that of a fresh artery. No statistically 
significant difference was found amongst the three groups. 
 
Figure 26: Suture retention strength between fresh, decell, and decell+needle scaffolds. ^ indicates that 
the value was derived from literature in the field. (a) Initial loading and preconditioning of the sample into 
the MTS machine (b) Failure point of the suture retention test (c) Suture retention strength (n=4 Decell, 
n=4 Decell+Needle) ^ from Conklin, 2002 
 
3.3.1.7 Burst Pressure 
Figure 27 shows the burst pressures of fresh arteries, decellularized arteries, and 
decellularized arteries with microneedle injections of 1X PBS. The burst pressures of the 
decellularized scaffolds exceed that of a fresh artery. No statistically significant 





Figure 27: Burst pressures between fresh, decell, and decell+needle scaffolds. ^ indicates that the value 
was derived from literature in the field. (a) Testing apparatus to determine burst pressure (b) Burst pressure 
(n=3 Decell, n=2 Decell+Needle) ^ from Conklin, 2002; Cohut, 2001; Roeder, 2001 
 
3.3.1.8 Compliance 
 Compliance was defined as the inverse of Peterson's elastic modulus according to the 
following equation: C = (ΔD/D0)/ΔP. A tukey test in conjunction with an ANOVA to find 
means that are significantly different from each other (p<0.05) was performed, and 
results showed that decell and decell+needle are both significantly different from the 
fresh artery.  Trends in literature agree with this finding. Compliance tends to decreases 




Figure 28: Diametrical compliance amongst fresh, decell, and decell+needle scaffolds. * indicates 
statistical significance  ^ indicates that the value was derived from literature in the field. (a) Digital image 
taken at 80mmHg (b) Digital image taken at 120mmHg (c) Diametrical compliance (n=3 Decell, n=2 
Decell+Needle) ^ from Roy, 2005 
 
3.3.2 Aortic Cusp 
3.3.2.1 Tissue Decellularization 
Verification of decellularization was completed with histological staining. H&E was 
used to both detect the presence of nuclei and to visualize any potential damage to the 
ECM due to the decellularization process. Figure 29A shows the structure and 
composition of a fresh aortic cusp prior to decellularization and Figure 29B show the 
artery post decellularization. No nuclei were seen in the decellularized H&E sections, and 
the organization of the extracellular matrix appeared undamaged.  
DAPI stains nuclei bright, fluorescent blue. All of the nuclei present in Figure 29C 




Figure 29: Histological stains to verify decellularization (a) H&E stain of fresh porcine aortic cusp (b) 
H&E stain of decellularized porcine aortic cusp (c) DAPI stain of fresh porcine aortic cusp nuclei=blue (d) 
DAPI stain of decellularized porcine aortic cusp nuclei=blue 
 
3.3.2.2 H&E 
Cells are visible after seeding with the 9-microneedle hub and with the 30-gauge 
needle.  In Figure 30B, there appears to be some mechanical damage to the ECM of the 
cusp.  It is uncertain whether the needle created this damage.  In Figures 30C and 30D 
there is an abundance of cells within the pores of the scaffolds.  The cells seem evenly 





Figure 30: H&E staining to compare cellular presence after injection (a,b) Injection with 30G needle 
(c,d) Injection with 9-microneedle hub 
3.3.2.3 DAPI 
Figure 31B shows a large cluster of cells distributed through the tissue.  The tissue in 





Figure 31: DAPI staining to compare cellular presence after injection with 30G and 9-microneedle 
hub. Nucleus=blue. (a) Injection with a 30 Gauge needle (b) Injection with 9-microneedle hub 
 
3.3.2.4 Massons Trichrome 
Unlike the staining of the arteries, the cells in the cusps can be easily visualized with 
Massons Trichrome.  Figures 32C and 32D show cellular infiltration of the pores of the 





Figure 32: Massons Trichrome staining to detect cellular presence after injection. Collagen = blue, 
nuclei = dark red/ purple, cytoplasm = red/pink (a,b) Injection with 30G needle (c,d) Injection with 9-
microneedle hub 
3.3.2.5 Uniaxial Testing 
Results of statistical testing show no statistically significant difference in the ultimate 
tensile stress or Young’s modulus amongst fresh tissues, decellularized tissues, and 
decellularized tissues with repeated injections of PBS.  It can be concluded that repeated 




Figure 33: Uniaxial tensile testing to compare fresh, decell, and decell+needle scaffolds. ^ indicates 
that the value was derived from literature in the field. (a) Ultimate tensile strength (n=2 Decell, n=2 
Decell+Needle) ^ from Clark, 1971 (b) Young’s Modulus (n=2 Decell, n=2 Decell+Needle) ^ from Clark, 
1971(c) Stress strain curve used to determine ultimate tensile stress and Young’s modulus 
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CHAPTER 4: RESULTS AND DISCUSSION 
4.1 Microneedle Design 
Although all of the needles purchased for this experiment were forged from 
stainless steel, the strength of the needles varied extensively between the different arrays.  
The AdminPen did not physically contain solid needles, but instead there were 600um 
spikes adjacent to holes in the array to mimic needles.  The spikes were intended to create 
a hole in which fluid could flow into when the plunger in the syringe was pushed.   
 
Figure 34: “Microneedle” arrangement on circular hub.  (a) Hub is composed of a sticky, plastic 
material and filled with foam to maintain shape (AdminMed, Adminmed.com) (b,d,c) Images taken on 






This array was purchased for testing because it is inexpensive to fabricate and easily 
customizable; therefore, it could be a wise option to use instead of actual needles.  
However, the AdminPen immediately failed in preliminary testing.  The needle hub was 
poorly hand-made and contained gaps around the hub that allowed the fluid to escape.  
The needles were comparable to the physical characteristics of aluminum foil and 
immediately deformed when pressed against a tissue. 
Three MicronJet hubs were received in sterile packing from NanoPass. The arrays 
tightly screwed into the luer lock of a syringe and efficiently channeled fluid into the 
needles.  However, all three of the NanoPass arrays deformed within the first five 
injections.  In the first two cases, the needles immediately bent and could not be repaired 
without causing further damage to the device.   The MicronJet microneedles were made 
of silicon and this may have caused the failure of the needles.  Images of the damaged 




Figure 35: Magnified images of MicronJet after use. (a) After 10 uses the left two needles bent against 
the hub and the third needle changed angle (b) After single use the needles broke off of the array onto the 
cusp (c) After single use on a cusp, the needle shattered (d) After single use, no needles are visible without 
magnification 
 
The device clearly states that it is single-use only, but in the third case, the needle broke 
immediately with the first injection.  This device does not withstand the physical forces 
necessary for tissue recellularization with repeated injection. 
 The Micropoint Technologies 9-microneedle array was used in all preliminary 
and final studies, totaling about 1500 insertions. The needle was sterilized in the 




Figure 36: 9-microneedle hub after extensive use. (a) Magnified image of the needles (b) Needles appear 
to be at the same height and at 90° to the hub 
 
After 1500 insertions, the needles no longer have a 45° beveled tip, yet all needles retain 
an open channel and injection ability.  Use of the needle after the tip is dulled may have a 
negative effect on the mechanical properties of the scaffold.  The needles must pierce the 
tissue or else the tissue will only deform against the needles and not create a channel for 
injection. 
4.2 Experimentation: Injection Capability 
The microneedle array was successful at delivering cells to the aortic cusps, but 
faltered when used on the decellularized carotid arteries. This leads us to believe that the 
density of the tissue plays a significant role on the injectibility of the tissue. With respect 
to the arteries, some cells were able to penetrate the elastic wall, but the majority of the 
cells remained on the periphery of the vessel.  However, microneedles effectively 
distributed cells throughout the thickness and length of the cusp.  Cusps are more porous 
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and less dense than arteries and this allowed the needles to expel cells into the scaffolds 
with less resistance. 
Although cellular retention after injection into arteries was poor, the microneedle 
method still holds promise.  The microneedles met all the requirements of bulk seeding 
except one: safety, preservation of cellular viability, reduced seeding time, minimal 
damage to scaffold, and repeatability were each established; however, a high seeding 
density was not initially observed.   
These results could be partially attributed to the method used to evaluate cell 
density.  Histology was the sole method used to determine if the scaffolds were 
sufficiently seeded.  Histological slides are created from 5um sections of a tissue and 
only expose the cells in that section.  If a section was cut adjacent to where the cells 
reside, we may mistakenly assume that there are no cells in the scaffold.  Another method 
to count cells, such as flow cytometry, must be used in the future to determine how many 
cells remain on the scaffold post-seeding. 
Preliminary studies with the microneedles and decellularized arteries and cusps 
showed that a single 10µl bolus injection into the scaffold did not generate enough 
pressure to drive cells into the interior.  To counter this, several 10µL injections were 
made in the same place to increase pressure within the scaffold.  This multiple-injection 
method was used throughout the studies in this thesis and provided much better results. 




The needles did not exceed the depth of the tissue, and thereby eliminated the 
issues associated with injection by hypodermic needles.  No needle holes were made that 
permeabilized the tissue.  Figure 37 shows the tissues after they were injected with the 
cell suspension.  Although faint, there is evidence of the 9-needle grid shown on both the 
artery and the cusp.  The small pink dots in the tissue represent the cell suspension 
beneath the outer layer of the tissue.  When these dots were visualized, the injection was 
considered to be successful. 
 
Figure 37: Tissues post injection. (a) The black circle surrounds the imprint of the nine needles after a 
20uL suspension was injected into the carotid artery scaffold (b) Manner of injection with the repeat 
dispenser (C) The black circle surrounds the imprint of the nine needles after a 20uL suspension was 
injected into the aortic cusp scaffold 
 
Several studies have been published on the fluid dynamics of liquid flow through 
microneedles (Amin, 2013; Wang, 2005; Maranto, 2006). These studies have found that 
single microneedles inserted into skin without retraction had flow rates of 15–96 µl/h, but 
partial retraction of microneedles increased flow rates up to 11.6-fold (Maranto, 2006). 
Also, by increasing the pressure at which the fluid was injected, the flow rate could be 
further increased.  The studies also concluded that dense dermal tissue compresses during 
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microneedle insertion and prevents fluid from leaving the needle tip.  Due to these 
results, we tried to retract the needle slightly after injection.  It is uncertain if this may 
have caused some of the cells to escape back out of the pore onto the exterior of the 
scaffold.  
Microneedles have the potential to become the standard of cell seeding, but some 
adjustments must be made to improve this seeding method.  The flow rate and pressure of 
the cell suspension leaving the syringe must be increased in order for cells to be firmly 
deposited into the scaffold. To accomplish this, a pressurized pump could be attached to 
the syringe.  The pump could be set to different pressure settings to meet the 
requirements of various tissues; for example, a cusp would require a lesser pressure than 
an artery.  Also, more concentrated cell suspensions could be injected into the tissue to 
increase the probability of cell adhesion.  A larger volume deposited into the scaffold 
could also assist in increasing injection pressure. 
4.3 Experimentation: Mechanical damage 
Results of the suture retention strength test, burst pressure test, and uniaxial tensile 
tests showed that repeated injection with microneedles did not have a negative effect on 
the scaffolds’ mechanical properties. Diametrical compliance decreased with the 
decellularization of the tissues but did not suffer due to repeat injections with 
microneedles.  Our lab has previously shown that tissue fixation with PGG tends to 
improve the strength and durability of the scaffolds, causing an increase in burst 
pressures and uniaxial mechanical properties.
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CHAPTER 5: CONCLUSIONS 
1. Microneedles can inject a high cell density in porous cardiovascular tissues, but 
falter when used in dense tissues  
2. Repeated injections with microneedles have negligible effects on the mechanical 
properties of the tissues 
3. Microneedle design, including needle height, array size, needle diameter, 
material, can be tailored to meet the needs of the specific tissue 
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CHAPTER 6: RECOMENDATIONS 
1. The pressure at which the cells are injected must be increased in order for 
microneedles to penetrate dense tissues and inject cells at a clinically relevant 
rate. The effects of higher pressure on cell viability must then be investigated 
2. Other decellularized tissues should be investigated, such as decellularized 
pericardium, decellularized aortic root, and decellularized myocardium 
3. Higher seeding densities must be tested 
4. Test microneedles with openings at the side of the needle instead of the tip to 
decrease the chance of tissue clogging 
5. A “robot” to automate the seeding of scaffolds should be investigated.  This 
robot should monitor seeding pressure, seeding depth, and seeding pattern across 
the scaffold 
6. Fresh tissue from the same batch of tissues that were decellularized should be 
used for mechanical testing instead of values from literature 
7. A long-term bioreactor study should be done to determine if cells proliferate, 
migrate, or differentiate over time.  The scaffolds from each long-term time point 
should undergo mechanical testing 
8. Live/Dead assays should be conducted at different time points during a long-term 
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